

REGULATORY MYELOID SUPPRESSOR CELLS:

From Basic Discovery to
Therapeutic Application

JUNE 16 - 19, 2016
PHILADELPHIA, PA


The international conference will present the most current and innovative immunotherapy research, with a focus on the pathological functions of myeloid-derived suppressor cells, dendritic cells, macrophages, and neutrophils.

6 sessions over the 4 days will examine the basic and translational aspects of regulatory myeloid cells in cancer and other pathological conditions.

Keynote SPEAKER:
Robert A. Weinberg, PhD
MIT and Whitehead Institute for
Biomedical Research

Register online at:
www.myeloidsuppressors.com

OUR SPONSORS:



Peregrine

Genentech
A Member of the Hoffmann-La Roche Group



Speakers & SESSIONS

Session 1, June 16th – Origin and natural history of regulatory myeloid cells

Dmitry I. Gabrilovich, *The Wistar Institute*; **Ming O. Li**, *Memorial Sloan Kettering Cancer Institute*; **Miriam Merad**, *Icahn School of Medicine at Mount Sinai*; **Suzanne Ostrand-Rosenberg**, *University of Maryland*, and **Mikael J. Pittet**, *Harvard University*

Session 2, June 16-17th – Mechanisms that control accumulation and function of regulatory myeloid cells

Scott Abrams, *Roswell Park Cancer Institute*; **Vincenzo Bronte**, *University of Verona*; **José R. Conejo-Garcia**, *The Wistar Institute*; **Juan R. Cubillos-Ruiz**, *Weill Cornell Medical College*; **Tim F. Greten**, *Center for Cancer Research, NCI*; **Augusto Ochoa**, *Louisiana State University*; **Antonio Sica**, *Humanitas Clinical and Research Center*, and **Jie Zhou**, *Sun Yet-Sen University*

Session 3, June 17th – Contribution of regulatory myeloid cells to immune responses

Michal Baniyash, *The Hebrew University of Jerusalem*; **Evgeniy B. Eruslanov**, *University of Pennsylvania*; **Zvi G. Fridlender**, *Hadassah University Medical Center*; **Luis J. Montaner**, *The Wistar Institute*; **Peter J. Murray**, *St. Jude Children's Research Hospital*, and **Viktor Umansky**, *German Cancer Research Center*

Session 4, June 18th – Contribution of regulatory myeloid cells to pathobiology of cancer

Mario Colombo, *Italian National Cancer Institute*; **Alberto Mantovani**, *Humanitas Clinical and Research Center*; **Jeffrey W. Pollard**, *The University of Edinburgh*; **Paulo Rodriguez**, *Louisiana State University*; **Jo van Ginderachter**, *Vrije Universiteit Brussels*; **Sheng Wei**, *H. Lee Moffit Cancer Center*, and **Weiping Zou**, *University of Michigan*

Session 5, June 18th – Clinical significance of regulatory myeloid cells

Sven Brandau, *University Hospital Essen*; **Graham Pawelec**, *University of Tübingen*, and **Jeffrey S. Weber**, *NYU Langone Medical Center*

Session 6, June 19th – Therapeutic targeting of myeloid cells

Ron N. Apte, *Ben-Gurion University of the Negev*; **Bruce R. Blazar**, *University of Minnesota*; **Ivan M. Borello**, *Johns Hopkins Sidney Kimmel Comprehensive Cancer Center*; **Shu-Hsia Chen**, *Mount Sinai School of Medicine*; **David G. DeNardo**, *Washington University*; **Rolf Kiessling**, *Karolinska Institutet*; **Marcin Kortylewski**, *City of Hope Cancer Center*; **Vinit Kumar**, *The Wistar Institute*; **David H. Munn**, *Georgia Regents University*, and **Michael Shurin**, *University of Pittsburgh*

PRESENTED AND
HOSTED BY:



THE WISTAR INSTITUTE